الصفحة الرئيسية>>Signaling Pathways>> Tyrosine Kinase>> VEGFR>>TIE-2/VEGFR-2 kinase-IN-1

TIE-2/VEGFR-2 kinase-IN-1

رقم الكتالوجGC60365

يستخدم TIE-2 / VEGFR-2 kinase-IN-1 لتخليق مثبطات TIE-2 و / أو VEGFR-2 ، المستخرجة من براءة الاختراع WO2003022852 ، المثال 14

Products are for research use only. Not for human use. We do not sell to patients.

TIE-2/VEGFR-2 kinase-IN-1 التركيب الكيميائي

Cas No.: 453590-24-4

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
615٫00
متوفر
1mg
232٫00
متوفر
5mg
510٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated with inappropriate angiogenesis[1].

Angiopoieten 1 is a ligand for the endotheiium-specific receptor tyrosine kinase, TIE-2 is a novel angiogenic factor[1].Inhibition of TIE-2 is expected to serve to disrupt remodeling and maturation of new vasculature initiated by angiogenesis thereby disrupting the angiogenic process. Inhibition at the kinase domain binding site of VEGFR-2 would block phosphorylation of tyrosine residues and serve to disrupt initiation of angiogenesis.

[1]. Jerry Leroy Adams, et al. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors. Patent WO2003022852.

مراجعات

Review for TIE-2/VEGFR-2 kinase-IN-1

Average Rating: 5 ★★★★★ (Based on Reviews and 3 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TIE-2/VEGFR-2 kinase-IN-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.